What type of study is this?

This is a Animal Study study (also classified as: In Vitro Study).

September 10, 2025Archiv der Pharmazie

Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors

View Full Paper

Ask AI

Bookmark

Authors

HFHossein Fasihi NNNima Naderi AGAmir Garmabdari

Discussion

Member takes

Overview

Synthesis reveals promising antidiabetic effects in diabetic rats and improved glucose tolerance in mice, indicating significant therapeutic potential.

Key Points

Daily administration of compound 5g led to a significant decrease in blood glucose levels in diabetic Wistar rats, suggesting its potential as an effective antidiabetic therapy.
Compound 5g exhibited an IC₅₀ of 23.08 nM against DPP-4, indicating a strong inhibitory activity compared to existing treatments.
In vivo testing showed that compound 5g performed comparably to sitagliptin in reducing plasma glucose during an oral glucose tolerance test in NMRI mice.
These findings support the potential development of compound 5g as a novel antidiabetic medication, highlighting significant therapeutic implications.

Cite This Study

Fasihi et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f27bc https://doi.org/10.1002/ardp.70077

View Full Paper

Ask AI

Bookmark

September 10, 2025Archiv der Pharmazie

Design, Synthesis and Antidiabetic Activity of Novel Pyrrole‐3‐Carboximidamide Derivatives as Dipeptidyl Peptidase‐4 Inhibitors

View Full Paper

Ask AI

Bookmark

Authors

HFHossein Fasihi NNNima Naderi AGAmir Garmabdari

Discussion

Member takes

Overview

Synthesis reveals promising antidiabetic effects in diabetic rats and improved glucose tolerance in mice, indicating significant therapeutic potential.

Key Points

Daily administration of compound 5g led to a significant decrease in blood glucose levels in diabetic Wistar rats, suggesting its potential as an effective antidiabetic therapy.
Compound 5g exhibited an IC₅₀ of 23.08 nM against DPP-4, indicating a strong inhibitory activity compared to existing treatments.
In vivo testing showed that compound 5g performed comparably to sitagliptin in reducing plasma glucose during an oral glucose tolerance test in NMRI mice.
These findings support the potential development of compound 5g as a novel antidiabetic medication, highlighting significant therapeutic implications.

Cite This Study

Fasihi et al. (2025) studied this question.

synapsesocial.com/papers/68c1c64554b1d3bfb60f27bc https://doi.org/10.1002/ardp.70077

Also Consider

Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark